- Home
- CBZ vs DNLI Comparison
CBZ vs DNLI Comparison
Compare CBZ & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBZ | DNLI |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CBZ | DNLI |
|---|---|---|
| Price | $54.39 | $17.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $31.58 |
| AVG Volume (30 Days) | 502.5K | ★ 1.7M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $2,675,607,000.00 | N/A |
| Revenue This Year | $55.67 | N/A |
| Revenue Next Year | $6.13 | $3,973.10 |
| P/E Ratio | $32.02 | ★ N/A |
| Revenue Growth | ★ 59.19 | N/A |
| 52 Week Low | $47.89 | $10.57 |
| 52 Week High | $90.13 | $24.35 |
Technical Indicators
Market Signals| Indicator | CBZ | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 59.60 | 50.96 |
| Support Level | $52.46 | $15.34 |
| Resistance Level | $54.42 | $17.95 |
| Average True Range (ATR) | 1.59 | 0.74 |
| MACD | 0.19 | 0.00 |
| Stochastic Oscillator | 93.65 | 72.22 |
Price Performance
Historical ComparisonAbout CBZ CBIZ Inc.
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the majority of its revenues from the Financial Services segment and geographically from the United States.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.